接种疫苗
免疫学
免疫
抗体
中和抗体
体液免疫
免疫
免疫系统
病毒学
支气管肺泡灌洗
医学
生物
肺
内科学
作者
Jialei Tang,Cong Zeng,Thomas C. Cox,Chaofan Li,Young Min Son,In Su Cheon,Yue Wu,Supriya Behl,Taylor Jj,Rana Chakraborty,Aaron J. Johnson,Dante Schiavo,James P. Utz,Janani Reisenauer,David E. Midthun,John J. Mullon,Eric S. Edell,Mohamad-Gabriel Alameh,Larry Borish,W. Gerald Teague,Mark H. Kaplan,Drew Weissman,Ryan Kern,Haitao Hu,Robert Vassallo,Shan-Lu Liu,Jie Sun
出处
期刊:Science immunology
[American Association for the Advancement of Science (AAAS)]
日期:2022-10-28
卷期号:7 (76)
被引量:157
标识
DOI:10.1126/sciimmunol.add4853
摘要
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.